Abstract | OBJECTIVE: METHODS: RESULTS: At 6 months, the change in A1C from baseline (8.3%) was -0.56% (P < 0.05; n = 59). Pramlintide treatment significantly reduced mean postprandial glucose excursions (P < 0.05) and weight (-2.8 kg; P < 0.05; n = 125). Glycemic benefits were achieved with lower mealtime insulin doses (-10.3%; P < 0.05; n = 104). Nausea, primarily mild to moderate, was reported by 29.5% of patients (severe nausea in 2.4%). Rates of severe hypoglycemia were low (0.04 events/patient-year). CONCLUSIONS:
|
Authors | Diane Karl, Athena Philis-Tsimikas, Tamara Darsow, Gayle Lorenzi, Terrie Kellmeyer, Karen Lutz, Yan Wang, Juan P Frias |
Journal | Diabetes technology & therapeutics
(Diabetes Technol Ther)
Vol. 9
Issue 2
Pg. 191-9
(Apr 2007)
ISSN: 1520-9156 [Print] United States |
PMID | 17425446
(Publication Type: Clinical Trial, Journal Article, Multicenter Study)
|
Chemical References |
- Amyloid
- Blood Glucose
- Glycated Hemoglobin A
- Hypoglycemic Agents
- Insulin
- Islet Amyloid Polypeptide
- pramlintide
|
Topics |
- Adult
- Aged
- Amyloid
(therapeutic use)
- Blood Glucose
(analysis)
- Body Mass Index
- Diabetes Mellitus, Type 2
(blood, drug therapy)
- Drug Therapy, Combination
- Female
- Glycated Hemoglobin
(metabolism)
- Humans
- Hypoglycemic Agents
(therapeutic use)
- Insulin
(therapeutic use)
- Islet Amyloid Polypeptide
- Male
- Middle Aged
- Postprandial Period
- Treatment Outcome
|